Key Insights
Moderna's mRNA-1010 vaccine achieved a 26.6% higher efficacy than standard-dose flu vaccines in adults aged 50 and older.
The FDA's Vaccines and Related Biological Products Advisory Committee unanimously voted 9-0 in favor of mRNA-1010's benefit-risk profile in June 2026.
A Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026, has been set for the FDA's final decision on mRNA-1010.
AI Analysis
If approved, mRNA-1010 is expected to become a significant player in the influenza vaccine market, potentially capturing a substantial share due to it...
Market Outlook
Short-Term
The FDA's decision on mRNA-1010 by August 5, 2026, will be a critical catalyst for Moderna's stock performance.
Long-Term
Recent News
FDA reverses course, agrees to review Moderna’s mRNA flu vaccine
Drug Discovery TrendsContinue your research
Keep researching Moderna Mrna Influenza Vaccine August 2026
Move from the topic summary into related coverage, article-level impact analysis, and the next scheduled catalyst.
Explore market intelligence
Connect this story to current themes across macro, equities, commodities, and risk.
Follow AI financial news
Find related coverage ranked around the assets and market themes you follow.
Analyze a market story
Review sentiment, relevance, likely impact, timeframe, confidence, and uncertainty.
Prepare for market events
Check scheduled catalysts and create event-specific email reminders with optional AI context.
Unlock the full Moderna Mrna Influenza Vaccine August 2026 analysis
Get AI-powered insights, alerts, and market analysis for Moderna Mrna Influenza Vaccine August 2026 and other topics you follow.
No credit card required